Paul Sweeney
Impact in
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
- Oncology top 10%
Papers in
-
- Cancer, Hypoxia, and Metabolism 9
- Surgery 22
- Bladder and Urothelial Cancer Treatments 7
- Genital Health and Disease 5
- Co-authors
- Colin P. Dinney (15 shared papers)Joel W. Slaton (8 shared papers)Takashi Karashima (9 shared papers)Keiji Inoue (5 shared papers)David James McConkey (4 shared papers)Louis L. Pisters (5 shared papers)Paul Perrotte (4 shared papers)Daniel J. Hicklin (3 shared papers)
- Journals
- The Journal of Urology (7 papers)British Journal of Urology (3 papers)The Surgeon (3 papers)Applied Microbiology and Biotechnology (2 papers)World Journal of Urology (2 papers)
- Partner nations
- IrelandUnited StatesUnited Kingdom
In The Last Decade
Paul Sweeney
64 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 111
- Cancer Research 314
- Oncology 484
- Pulmonary and Respiratory Medicine 461
- Immunology 291
- Surgery 540
Countries citing papers authored by Paul Sweeney
This map shows the geographic impact of Paul Sweeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Sweeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Sweeney more than expected).
Fields of papers citing papers by Paul Sweeney
This network shows the impact of papers produced by Paul Sweeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Sweeney. The network helps show where Paul Sweeney may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Sweeney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. | 2000 | 203 |
| 2 | The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. | 2000 | 146 |
| 3 | Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. | 2003 | 128 |
| 4 | Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. | 2002 | 111 |
| 5 | Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. | 2003 | 111 |
| 6 | 1999 | 94 | |
| 7 | Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. | 2002 | 87 |
| 8 | 2003 | 86 | |
| 9 | Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. | 2002 | 84 |
| 10 | 2003 | 82 | |
| 11 | 1997 | 65 | |
| 12 | 2002 | 60 | |
| 13 | Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. | 2001 | 55 |
| 14 | 2001 | 54 | |
| 15 | Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. | 2000 | 48 |
| 16 | Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. | 2002 | 47 |
| 17 | 2007 | 44 | |
| 18 | 2016 | 39 | |
| 19 | 2016 | 38 | |
| 20 | 2011 | 35 |
About Paul Sweeney
Paul Sweeney is a scholar working on Cancer Research, Surgery, Biotechnology, Pulmonary and Respiratory Medicine and Urology, having authored 67 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (9 papers), Bladder and Urothelial Cancer Treatments (7 papers), Prostate Cancer Diagnosis and Treatment (6 papers), Angiogenesis and VEGF in Cancer (6 papers), Cancer Research and Treatments (5 papers), Genital Health and Disease (5 papers), Renal cell carcinoma treatment (5 papers) and Immunotherapy and Immune Responses (4 papers). The work is most often cited by research in Cancer Research (314 citations), Oncology (484 citations), Pulmonary and Respiratory Medicine (461 citations), Immunology (291 citations) and Surgery (540 citations). Paul Sweeney has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Colin P. Dinney, Joel W. Slaton, Takashi Karashima, Keiji Inoue, David James McConkey, Louis L. Pisters, Paul Perrotte, Daniel J. Hicklin, Daniel Josef Kedar and Randall E. Millikan. Their work appears in journals such as The Journal of Urology, British Journal of Urology, The Surgeon, Applied Microbiology and Biotechnology and World Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.